Peregrine portfolio company Ribon Therapeutics secured a $25 million equity investment from Pfizer to advance its potentially first-in-class oral small molecule programs in oncology and immunology. The investment supports the clinical development of RBN-2397, a PARP7 inhibitor for cancer, and RBN-3143, a PARP14 inhibitor for inflammatory diseases, as well as further development of Ribon’s proprietary BEACON+ platform. As part of the investment, Pfizer also brought its global development expertise to support Ribon’s pipeline, with Robert Rickert, Pfizer’s Senior Vice President and Head of Cancer Immunology Discovery, joining Ribon’s Scientific Advisory Board.
Official announcement: Ribon Therapeutics
